Post Market Clinical Follow-Up for ED Coil / Electro-detach Generator v4
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
Antwerp
-
Edegem, Antwerp, Belgium, 2650
- Not yet recruiting
- UZA Atwerp
-
Contact:
- Voormolen
- Phone Number: 038214848
- Email: Maurits.Voormolen@uza.be
-
Principal Investigator:
- Maurits Voormolen
-
-
-
-
Nordrhein-Westfalen
-
Bochum, Nordrhein-Westfalen, Germany, 44892
- Recruiting
- Knappschaftskrankenhaus Bochum
-
Principal Investigator:
- Sebastian Fischer
-
Contact:
- Fischer
- Phone Number: 02342993801
- Email: sebastian.fischer@kk-bochum.de
-
Principal Investigator:
- Werner Weber
-
-
Schleswig-Holstein
-
Lübeck, Schleswig-Holstein, Germany, 23538
- Recruiting
- Universitätsklinikum Schleswig-Holstein
-
Contact:
- Schramm
- Phone Number: 045150017215
- Email: Ramona.Schramm@uksh.de
-
Principal Investigator:
- Peter Schramm
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients are over 18 years of age.
- Patients will undergo catheter embolization using the Kaneka ED Coil with the ED Detach Generator v4 for aneurysm, arteriovenous malformation (AVM), or arteriovenous fistula (AFV)
- The patient, or his/her representative, has agreed to the informed consent.
Exclusion Criteria:
- The patient, or his/her representative, is unwilling or unable to agree to the informed consent.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Performance Measure
Time Frame: At 6 months
|
The recanalization in aneurysms will be classified using the Raymond-Roy Classification.
The outcomes following embolization of arteriovenous malformations and arteriovenous fistula will be classified as follows complete occlusion/subtotal occlusion/ partial occlusion
|
At 6 months
|
|
Performance Measure
Time Frame: At 12 months
|
The recanalization in aneurysms will be classified using the Raymond-Roy Classification.
The outcomes following embolization of arteriovenous malformations and arteriovenous fistula will be classified as follows complete occlusion/subtotal occlusion/ partial occlusion
|
At 12 months
|
|
Safety Measure - Assessment of Adverse Events
Time Frame: During 12 months
|
All adverse events will be recorded, along with their seriousness and relatedness to the device or the procedure.
|
During 12 months
|
|
Technical Measure
Time Frame: At embolization procedure, an average of 1 week
|
The technical properties of the ED Electrodetach Generator v4 will be assessed by successful coil detachment (yes/no)
|
At embolization procedure, an average of 1 week
|
|
Technical Measure
Time Frame: At embolization procedure, an average of 1 week
|
The technical properties of the ED Electrodetach Generator v4 will be assessed by the the number of detachment attempts
|
At embolization procedure, an average of 1 week
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ED Coil Prosp
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.